Reagentia en instrumenten voor immunologie, celbiologie en moleculaire biologie.
 

Biomarker Development and Validation Services

Biomarkers are now central to the advancement of precision medicine, particularly in oncology. They enable a deeper understanding of disease pathophysiology and are instrumental in patient stratification, predicting therapeutic responses, and monitoring clinical progression with enhanced accuracy. As companion diagnostics, biomarkers are essential for identifying patients most likely to benefit from targeted or immunomodulatory therapies.

At CliniSciences, we support your programs by providing access to cutting-edge analytical technologies and proven expertise in biomarker assay development and validation. Our CRO team applies a rigorous and tailored approach to identify, qualify, and validate exploratory or predictive biomarkers, in full compliance with regulatory requirements.

Biomarkers are involved at every stage of the drug development cycle, including:

  • Mechanism of action elucidation

  • Pharmacokinetic/pharmacodynamic (PK/PD) modeling

  • Therapeutic response evaluation

  • Monitoring safety and tolerability

Because methodological robustness is critical, we implement highly sensitive, specific, and reproducible assays, tailored to your biological matrices and scientific goals. The choice of technology (e.g., ELISA, multiplexing, immunohistochemistry, RT-qPCR, NGS) is discussed upfront to ensure reliability, clinical relevance, and regulatory success.

With our network of scientific experts and deep-rooted scientific culture, CliniSciences positions itself as a strategic partner to help transform your biomarker research into actionable tools for therapeutic decision-making.

We can provide:

/upload/sample-preparation-10-bpw2ad.jpg

 

/upload/s-sgtzqn.jpg